OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling

Wan-Chi Tsai; Li-Yuan Bai; Yi-Jin Chen; Po-Chen Chu; Ya-Wen Hsu; Aaron M. Sargeant; Jing-Ru Weng

doi:10.18632/oncotarget.16450

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling

Wan-Chi Tsai, Li-Yuan Bai, Yi-Jin Chen, Po-Chen Chu, Ya-Wen Hsu, Aaron M. Sargeant and Jing-Ru Weng _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:29233-29246. https://doi.org/10.18632/oncotarget.16450

Metrics: PDF 1470 views | HTML 1920 views | ?

Abstract

Wan-Chi Tsai1,2, Li-Yuan Bai3,4, Yi-Jin Chen1, Po-Chen Chu5,6, Ya-Wen Hsu7, Aaron M. Sargeant8, Jing-Ru Weng9

1Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

2Center for Infectious Disease and Cancer Research, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

3College of Medicine, China Medical University, Taichung 40402, Taiwan

4Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung 40447, Taiwan

5Institute of Biological Chemistry, Academia Sinica, Taipei 11574, Taiwan

6Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan

7Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy & Science, Tainan 71745, Taiwan

8Charles River Laboratories, Safety Assessment, Spencerville, OH 45887, USA

9Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 80424, Taiwan

Correspondence to:

Jing-Ru Weng, email: [email protected]

Keywords: OSU-A9, pancreatic cancer, p38, JAK, STAT3

Received: January 05, 2016 Accepted: February 27, 2017 Published: March 22, 2017

ABSTRACT

Pancreatic cancer is an aggressive malignancy that is the fourth leading cause of death worldwide. Since there is a dire need for novel and effective therapies to improve the poor survival rates of advanced pancreatic cancer patients, we analyzed the antitumor effects of OSU-A9, an indole-3-carbinol derivative, on pancreatic cancer cell lines in vitro and in vivo. OSU-A9 exhibited a stronger antitumor effect than gemcitabine on two pancreatic cancer cell lines, including gemcitabine-resistant PANC-1 cells. OSU-A9 treatment induced apoptosis, the down-regulation of Akt phosphorylation, up-regulation of p38 phosphorylation and decreased phosphorylation of JAK and STAT3. Cell migration and invasiveness assays showed that OSU-A9 reduced cancer cell aggressiveness and inhibited BxPC-3 xenograft growth in nude mice. These results suggest that OSU-A9 modulates the p38-JAK-STAT3 signaling module, thereby inducing cytotoxicity in pancreatic cancer cells. Continued evaluation of OSU-A9 as a potential therapeutic agent for pancreatic cancer thus appears warrented.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16450

Publication Alerts

Research Papers:

OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling

Abstract